Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Polymyxin B sulf [systemic] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
Polymyxin B sulf [eye] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
Polymyxin B sulfate [skin] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
polymyxin B-sulfat 100 % pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
polymyxin B-sulfat + trimethoprim øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
polymyxin B-sulfat + bacitracinzink øjensalve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
polymyxin B-sulfat + trimethoprim øjensalve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
polymyxin B-sulfat + bacitracinzink 10.000 enheder/500 enheder øjensalve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
Bacitracin zinc + neomycin sulfate + polymyxin b sulfate 400unt/5mg/10000unt ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
bacitracinzink 500 enheder + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/5 mg/1,6 mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/5 mg/10.000 opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
hydrocortison 10 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/7,5 mg/10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
hydrocortison 10 mg + neomycinsulfat 7,5 mg + polymyxin B-sulfat 1.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
hydrocortisonacetat 5 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder creme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
neomycinsulfat + polymyxin B-sulfat + prednisolonacetat 0,35 %/10.000 enheder/0,5 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
polymyxin B-sulfat + trimethoprimsulfat 10.000 enheder/1 mg opløsning til oftalmisk anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
neomycinsulfat + polymyxin B-sulfat + prednisolonacetat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
gramicidin + neomycinsulfat + polymyxin B-sulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
Polymyxin b sulfate + trimethoprim sulfate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
bacitracinzink + neomycinsulfat + polymyxin B-sulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
hydrocortison + neomycinsulfat + polymyxin B-sulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
dexamethason + neomycinsulfat + polymyxin B-sulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
Bacitracin zinc + polymyxin b sulfate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
Polymyxin B sulfate 500,000u powder for injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
Product containing hydrocortisone and neomycin sulfate and polymyxin B sulfate and zinc bacitracin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Polymyxin B sulfate |
Inferred relationship |
Some |
|
Polymyxin B (as polymyxin B sulfate) 500000 unit powder for solution for injection vial |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Polymyxin B sulfate |
Inferred relationship |
Some |
1 |